Study #2022-1047
Safety and efficacy of targeting PP2A in ovarian clear cell carcinoma using Dostarlimab and LB-100
MD Anderson Study Status
Enrolling
Treatment Agent
Dostarlimab, LB-100
Description
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Clear Cell Carcinoma
Study phase:
Physician name:
Amir Jazaeri
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.